AU2021276623A1 - 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2'-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression - Google Patents

3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2'-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression Download PDF

Info

Publication number
AU2021276623A1
AU2021276623A1 AU2021276623A AU2021276623A AU2021276623A1 AU 2021276623 A1 AU2021276623 A1 AU 2021276623A1 AU 2021276623 A AU2021276623 A AU 2021276623A AU 2021276623 A AU2021276623 A AU 2021276623A AU 2021276623 A1 AU2021276623 A1 AU 2021276623A1
Authority
AU
Australia
Prior art keywords
groups
compound
chosen
pharmaceutically acceptable
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021276623A
Other languages
English (en)
Inventor
Masaki DAINI
Tomoaki Hasui
Shuhei Ikeda
Toshihiro Imaeda
Hiroyuki Kakei
Makoto Kamata
Satoshi Mikami
Shinji Morimoto
Minoru Nakamura
Shinji Nakamura
Yuya Oguro
Kazuaki Takami
Sachie TAKASHIMA
Chunxiang Wang
Fumie Yamaguchi
Toru Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2021276623A1 publication Critical patent/AU2021276623A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021276623A 2020-05-22 2021-05-20 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2'-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression Pending AU2021276623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-090111 2020-05-22
JP2020090111A JP2021183587A (ja) 2020-05-22 2020-05-22 複素環化合物
PCT/IB2021/000337 WO2021234451A1 (en) 2020-05-22 2021-05-20 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression

Publications (1)

Publication Number Publication Date
AU2021276623A1 true AU2021276623A1 (en) 2022-12-22

Family

ID=76797026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021276623A Pending AU2021276623A1 (en) 2020-05-22 2021-05-20 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2'-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression

Country Status (13)

Country Link
US (1) US12590086B2 (cg-RX-API-DMAC10.html)
EP (1) EP4153581B1 (cg-RX-API-DMAC10.html)
JP (3) JP2021183587A (cg-RX-API-DMAC10.html)
KR (1) KR20230015946A (cg-RX-API-DMAC10.html)
CN (1) CN116171276A (cg-RX-API-DMAC10.html)
AR (1) AR122143A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021276623A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022023503A2 (cg-RX-API-DMAC10.html)
CA (1) CA3178798A1 (cg-RX-API-DMAC10.html)
IL (1) IL298275A (cg-RX-API-DMAC10.html)
MX (1) MX2022014576A (cg-RX-API-DMAC10.html)
TW (1) TW202208346A (cg-RX-API-DMAC10.html)
WO (1) WO2021234451A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021183586A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
GB202206054D0 (en) * 2022-04-26 2022-06-08 Cerevance Ltd Novel Compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
DE19736352C1 (de) 1997-08-21 1998-12-10 Atotech Deutschland Gmbh Vorrichtung zur Kontaktierung von flachem Behandlungsgut in Durchlaufgalvanisieranlagen
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
US8148367B2 (en) 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2011145735A1 (ja) * 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
AU2019312296B2 (en) * 2018-07-27 2025-05-29 Arcus Biosciences, Inc. Pyridone A2R antagonists
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
JP2020090111A (ja) 2018-12-03 2020-06-11 パイオニア株式会社 発光システム
JP2021183586A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
BR112022023503A2 (pt) 2023-01-17
JP2023528281A (ja) 2023-07-04
MX2022014576A (es) 2023-02-14
WO2021234451A1 (en) 2021-11-25
JP2025170366A (ja) 2025-11-18
JP7734153B2 (ja) 2025-09-04
IL298275A (en) 2023-01-01
JP2021183587A (ja) 2021-12-02
TW202208346A (zh) 2022-03-01
AR122143A1 (es) 2022-08-17
CN116171276A (zh) 2023-05-26
US12590086B2 (en) 2026-03-31
EP4153581A1 (en) 2023-03-29
EP4153581B1 (en) 2026-07-01
US20230357220A1 (en) 2023-11-09
KR20230015946A (ko) 2023-01-31
CA3178798A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7379374B2 (ja) 複素環化合物
AU2017245125B2 (en) Heterocyclic compound
CA3163200A1 (en) Heterocyclic compound
EP4153583B1 (en) 1-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of depression
US11827601B2 (en) Heterocyclic NMDA antagonists
JP7541487B2 (ja) 複素環化合物及びその用途
EP3239150B1 (en) Heterocyclic compound
WO2019022179A1 (ja) 複素環化合物
JP2025170366A (ja) 例えばうつ病の治療方法において使用するためのgpr139拮抗薬としての3-((1h-ピラゾール-4-イル)メチル)-6’-(フェニル)-2h-(1,2’-ビピリジン)-2-オン誘導体および関連化合物
JP2025539434A (ja) 複素環化合物及びその用途
EA051899B1 (ru) Производные 3-((1н-пиразол-4-ил)метил)-6'-(фенил)-2н-(1,2'-бипиридин)-2-она и связанные с ними соединения как антагонисты рецептора gpr139 для применения в способе лечения, например, депрессии
HK40059391A (en) Heterocyclic compound and use thereof